연구성과로 돌아가기

2021 연구성과별 연구자 정보 (208 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Lee, Jeonghoon Lee, J 6 Seoul Natl Univ Hosp, Seoul, South Korea jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Lee, Jung Il Lee, JI 7 Gangnam Severance Hosp, Seoul, South Korea jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Kweon, Young Oh Kweon, YO 8 Kyungpook Natl Univ, Daegu, South Korea jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Weltman, Martin Weltman, M 9 Nepean Hosp, Penrith, NSW, Australia jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Harrison, Stephen Harrison, S 10 Pinnacle Clin Res Ctr, San Antonio, TX USA GON-3283-2022 Harrison, Stephen jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Tetri, Brent Tetri, B 11 St Louis Univ, Sch Med, St Louis, MO USA jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Cusi, Kenneth Cusi, K 12 Univ Florida, Gainesville, FL USA ADV-2401-2022 Cusi, Kenneth jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Loomba, Rohit Loomba, R 13 UCSD, NAFLD Res Ctr, La Jolla, CA USA AAE-7831-2019 Loomba, Rohit jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Christianson, Dawn Christianson, D 14 Arrowhead Pharmaceut Inc, Pasadena, CA USA jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Rajicic, Natasa Rajicic, N 15 Arrowhead Pharmaceut Inc, Pasadena, CA USA jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH San Martin, Javier San Martin, J 16 Arrowhead Pharmaceut Inc, Pasadena, CA USA jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Hamilton, James Hamilton, J 17 Arrowhead Pharmaceut Inc, Pasadena, CA USA jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Mak, Lung Yi Loey Mak, LYL 18 Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China ABB-1599-2020 Mak, Lung Yi (Loey) jhamilton@arrowheadpharma.com;
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Yuen, Man-Fung Yuen, MF 19 Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China C-4466-2009 Yuen, Richard Man Fung jhamilton@arrowheadpharma.com;
ARO-HSD, AN INVESTIGATIONAL RNAi THERAPEUTIC, DEMONSTRATES REDUCTION IN ALT AND HEPATIC HSD17B13 mRNA AND PROTEIN IN PATIENTS WITH NASH OR SUSPECTED NASH Mak, Lung-Yi Mak, LY 1 Univ Hong Kong, Med, Hong Kong, Peoples R China ABB-1599-2020 Mak, Lung Yi (Loey)
페이지 이동: